Archive
Proactive news snapshot: ValiRx, PowerHouse Energy, Chaarat Gold …
A glance at some of the day's highlights from the Proactive Investors newswire
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 8 of 16
One Media IP leaps as former BBC boss Michael Grade invests in the music rights holder
A look at some of the biggest risers and fallers on Monday in London
ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
FTSE 100 closes higher as US tax reform hopes cheer global traders
The UK blue chip index closed up 46.44 points at 7,537
Archive
Proactive news snapshot: ValiRx, W Resources, Falcon Oil & Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Surprise trading update is just the job for Robert Walters
The trading update was short and sweet. Liberum responded by increasing its target price.
ValiRx surges once again as top-line data from Phase II lung cancer trial impresses
ValiRx said its VAL401 anti-cancer compound had a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer
FTSE 100 closes higher as energy stocks provide a boost; supermarkets weigh
Robert Walters sprang a pleasant surprise on the market with an unscheduled trading update.
ValiRx says YA II has converted second tranche of convertible loan facility at 1.25p per share
The life sciences company said YA II has elected to convert US$696,202.90 of its loan note, plus accrued interest of US$10,530, into 47,765,035 ordinary shares
ValiRx surges as it raises £1mln at a premium and confirms VAL401 phase II trial on track for readout this year
The £1mln will be used to advance the clinical trial of its lead compound, VAL201, as well as for advancing other pre-clinical programmes
Archive
Proactive news snapshot: Greatland Gold, SDX Energy, Asiamet Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Rurelec shares more than double as power plant operator confirms takeover talks
A look at some of the biggest risers and fallers today in London
ValiRx awarded fifth US patent for VAL401 cancer drug
“It is really pleasing to receive this notification of allowance for this latest VAL401 patent so close on the heels after our encouraging and positive announcement of first verified clinical data emerging from the VAL401 trial
FTSE 100 closes lower ahead of FOMC minutes
The FTSE 100 index closed down 4.46 at 7,533, below the session peak of 7,550.17 but above the low of 7,519.60
Petra Diamonds' shares sparkle after Tanzania lifts export ban
The government of Tanzania has given Petra the go-ahead to resume diamond exports and sales from the Williamson mine.
ValiRx opens higher as it completes dosing of VAL401 phase II cancer trial
Finial analyses from the study is expected by the end of the year